Vanda Pharmaceuticals Inc. develops and commercializes innovative therapies for central nervous system disorders and other conditions with high unmet medical needs. Its products include Hetlioz for non-24-hour sleep-wake disorder and Smith-Magenis syndrome, and Fanapt for the treatment of schizophrenia. The company utilizes genetic and genomic approaches in its drug discovery and development activities.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 50 | — | -29.5 | — |
| Q2 2025 | 52.6 | — | -27.2 | — |
| Q3 2025 | 56.3 | — | -22.6 | — |
| Q4 2025 | 57.2 | — | -141.2 | — |
| Q1 2026 | 51.7 | 3.4% | -48.6 | — |
| Q2 2026 | 50.5 | -3.9% | -62.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Anbio Biotechnology (NNNN), Aviat Networks, Inc. (AVNW), Solarius Capital Acquisition Corp. (SOCA), PAMT CORP (PAMT), Pyxis Oncology, Inc. (PYXS), Invest Green Acquisition Corporation (IGAC)